Cabergoline in the treatment of early Parkinson's disease: Results of the first year of treatment in a double-blind comparison of cabergoline and levodopa

Neurology

Volumn 48, Issue 2, 1997, Pages 363-368

  Rinne, U K ^a   Bracco, F ^b   Chouza, C ^c   Dupont, E ^d   Gershanik, O ^e   Marti Masso, J F ^f   Montastruc, J L ^g   Marsden, C D ^h   Dubini, A ⁱ   Orlando, N ^j   Grimaldi, R ⁱ  

^a UNIVERSITY OF TURKU   (Finland)

^b UNIVERSITY OF PADOVA   (Italy)

^c UNIVERSIDAD DE MONTEVIDEO   (Uruguay)

^d AARHUS UNIVERSITY HOSPITAL   (Denmark)

^e HOSPITAL FRANCÉS   (Argentina)

^f Hospital Nuestra Senora de Aranzazu   (Spain)

^g CHU PURPAN   (France)

^h NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

ⁱ PFIZER INC   (United States)

^j SENDO Tech Srl   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BROMOCRIPTINE; CABERGOLINE; CARBIDOPA; LEVODOPA;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DYSPEPSIA; EDEMA; FEMALE; GASTRITIS; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PARKINSON DISEASE; PRIORITY JOURNAL; SLEEP DISORDER; VERTIGO;

EID: 0031026244     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.48.2.363     Document Type: Article

References (30)

1. Lees AJ. L-Dopa treatment and Parkinson's disease. Q J Med 1986;59:535-547.
2. Lesser RP, Fahn S, Snider SR, Cote LJ, Isgreen WP, Barrett RE. Analysis of the clinical problems in parkinsonism and the complications of long-term levodopa therapy. Neurology 1979; 29:1253-1260.
3. Hoehn M. Using bromocriptine to manage the inadequacies of L-dopa therapy. In: Fahn S, Marsden CD, Jenner P, Teychenne PF, eds. Recent developments in Parkinson's disease. New York: Raven Press, 1985:293-301.
4. Rinne UK. Treatment of Parkinson's disease: problems with a progressing disease. J Neural Transm 1981;51:161-174.
5. Leenders KL, Palmer AJ, Quinn N, et al. Brain dopamine metabolism in patients with Parkinson's disease measured with positron emission tomography. J Neurol Neurosurg Psychiatry 1986;49:853-860.
6. Rodriguez M, Lera G, Vaamonde J, Luquin MR, Obeso JA. Motor response to apomorphine and levodopa in asymmetric Parkinson's disease. J Neurol Neurosurg Psychiatry 1994;57: 562-566.
7. Bravi D, Mouradian MM, Roberts JW, Davis TL, Sohn YH, Chase TN. Wearing-off fluctuations in Parkinson's disease: contribution of postsynaptic mechanisms. Ann Neurol 1994; 36:27-31.
8. Stern G, Lees A. Long-term effects of bromocriptine given to de novo patients with idiopathic Parkinson's disease. In: Yahr MD, Bergmann KJ, eds. Adv Neurol, vol 45. New York: Raven Press, 1986;525-527.
9. Rinne UK. Early combination of bromocriptine and levodopa in the treatment of Parkinson's disease: a 5-year follow-up. Neurology 1987;37:826-828.
10. Marsden CD, Fahn S. Problems in Parkinson's disease and other akinetic-rigid syndromes. In: Marsden CD, Fahn S, eds. Movement disorders 2. London: Butterworths & Co (Publishers) Ltd. 1987:65-72.
11. Melamed E. Initiation of levodopa therapy in Parkinsonian patients should be delayed until the advanced stages of the disease. Arch Neurol 1986;43:402-405.
12. Alberts MJ, Stajich J, Olanow CW. A randomised blinded study of low-dose bromocriptine versus low-dose carbidopa/ levodopa in untreated Parkinson's patients. In: Fahn S, Marsden CD, eds. Recent developments in Parkinson's disease. New York: MacMillan, 1987:201-208.
13. Hely MA, Morris JGL, Rail D, et al. The Sydney Multicentre Study of Parkinson's Disease: a report on the first 3 years. J Neurol Neurosurg Psychiatry 1989;52:324-328.
14. Libman I, Gawel MJ, Riopelle RJ, Bouchard S. A comparison of bromocriptine (Parlodel®) and levodopa-carbidopa (L-dopa/ carbidopa®) for treatment of 'de novo' Parkinson's disease patients. Can J Neurol Sci 1987;14:576-580.
15. Montastruc JL, Rascol O, Senard JM, Rascol A. A randomized controlled study comparing bromocriptine to which levodopa was later added, with levodopa alone in previously untreated patients with Parkinson's disease: a five year follow-up. J Neurol Neurosurg Psychiatry 1994;57:1034-1038.
16. Nakanishi T, Iwata M, Goto I, et al. Second interim report of the Nation-Wide Collaborative Study on the Long-Term Effects of Bromocriptine in the Treatment of Parkinsonian Patients. Eur Neurol 1989;29:3-8.
17. Rinne UK. Early dopamine agonist therapy in Parkinson's disease. Mov Disord 1989;4:S86-S94.
18. Wolters EC, Tissingh G, Bergmans PLM, Kuiper MA. Dopamine agonists in Parkinson's disease. Neurology 1995; 45(suppl 3):S28-S34.
19. Rinne UK. Lisuride, a dopamine agonist in the treatment of early Parkinson's disease. Neurology 1989;39:336-339.
20. Strolin Benedetti M, Cocchiara G, Battaglia R, et al. Pharmacokinetic and metabolic pattern of cabergoline, a long-acting dopamine agonist, in healthy volunteers. Presented at the 10th International Symposium on Parkinson's Disease; October 19, 1991; Tokyo.
21. Bergström M, Hartvig P, Nava C, De Paolis C, Längström B. Effect of cabergoline on striatal receptor binding and dopamine synthesis: in vivo study in monkeys with positron emission tomography. Presented at The Meeting of European Neuroscience; September 3-7, 1995; Amsterdam.
22. Fahn S, Elton RL, and Members of the UPDRS Development Committee. Unified Parkinson's Disease Rating Scale. In: Fahn S, Marsden CD, Calne DB, Goldstein M, eds. Recent developments in Parkinson's disease, vol 2. Florham Park, NJ: MacMillan Healthcare Information, 1987:153-163.
23. Snedecor GW. Statistical methods. Ames, Iowa: The Iowa State University Press, 1964:1-34, 97-98, 217-219.
24. Kalbfleisch JD, Prentice RL. The statistical analysis of failure time data. New York: John Wiley & Sons, 1980:16-19.
25. Yanagisawa N, Kanazawa I, Goto I, Kowa H, Kuno S, Mizuno Y. Seven-year follow-up study of bromocriptine therapy for Parkinson's disease. Eur Neurol 1994;34:29-35.
26. Rinne UK. Combined bromocriptine-levodopa therapy early in Parkinson's disease. Neurology 1985;35:1196-1198.
27. Lera G, Vaamonde J, Rodrigues M, Obeso JA. Cabergoline in Parkinson's disease: long-term follow-up. Neurology 1993;43: 2587-2590.
28. Parkinson's Disease Research Group in the United Kingdom. Comparisons of therapeutic effects of levodopa, levodopa and selegiline, and bromocriptine in patients with early, mild Parkinson's disease: three year interim report. BMJ 1993;307: 469-472.
29. Quinn NP. Anti-parkinsonian drugs today. Drugs 1984;28: 236-262.
30. Goetz CG. Parkinson's disease and other parkinsonian syndromes. In: Klawans HL, Goetz CG, Tanner CM, eds. Textbook of clinical neuropharmacology and therapeutics. 2nd ed. New York: Raven Press, 1992;91-116.